ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.034,63
1,36%
S&P 500
5.770,20
0,55%
US Dollar vs BRL
5,7879
0,00%
Bitcoin
84.696,88
-1,69%
Brent Oil
70,235
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Inhibikase Therapeutics Inc (IKT)

  7. Inhibikase Therapeutics Inc (IKT) Notícias

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IKT
DataHoraFonteTítuloCódigoCompanhia
25/02/202518:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
25/02/202518:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/02/202510:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
14/02/202523:04Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
14/02/202517:45Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
04/02/202518:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IKTInhibikase Therapeutics Inc
17/01/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IKTInhibikase Therapeutics Inc
10/01/202518:37Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
05/12/202418:47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IKTInhibikase Therapeutics Inc
03/12/202408:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202418:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202410:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
08/11/202418:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202418:26Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202417:25GlobeNewswire Inc.Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/08/202409:00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:IKTInhibikase Therapeutics Inc
18/06/202418:27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202409:05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
05/06/202409:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/06/202417:11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IKTInhibikase Therapeutics Inc
22/05/202409:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
20/05/202409:01GlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202421:00GlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202409:45GlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202408:56Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
09/05/202415:41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
09/05/202409:00GlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
18/04/202417:30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
03/04/202409:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
27/03/202417:15GlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IKT

Seu Histórico Recente

AMEX
LABU
Direxion Daily S&P Biote...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios